Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL (clinicaltrials.gov) - Oct 1, 2026 - P2 | N=40 | Active, not recruiting | Sponsor: Massachusetts General Hospital | Recruiting ➔ Active, not recruiting
Enrollment closed • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Small Lymphocytic Lymphoma • BCL2
|